Inventaire - 友達とコミュニティはあなたのベストな図書館です - Inventaire

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013.

著者

Carlos Camps

Enriqueta Felip

Pilar Garrido

この作品が含まれる作品: Clinical and Translational Oncology

出版日: 2013-08-06

Cites articles 37

Date

タイトル

著者

2013-01

Cancer statistics, 2013
2013-07-01

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Marc Ladanyi, Erik Thunnissen, Jeremy A. Squire, Giuseppe Giaccone, Mary Beth Beasley
2013-03-01

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer

Eric Solary, Fabrice André, Jean-Charles Soria, Gwénaël Le Teuff, Jean-Pierre Pignon, Ming-Sound Tsao, Elisabeth Brambilla, Jean-Yves Douillard, Thierry Le Chevalier
2013-06-01

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer

Fiona Blackhall, Yi-Long Wu, Denis Moro-Sibilot, Tony Mok, Keith D Wilner, D Ross Camidge, Benjamin J Solomon, Alice T Shaw, Gregory J Riely
2013-06-17

Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2

Isabele A Small
2012-05-01

Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).

José Ramírez, Pilar Garrido, Enriqueta Felip
2012-11-20

Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients

Tristan D Yan
2012-02-16

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Cesare Gridelli
2012-03

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Angel Artal, Mariano Provencio, Vittorio Gebbia, Alessandra Bearz, Giuseppe Altavilla, Julien Mazieres, Pilar Garrido, Enriqueta Felip, Alain Vergnenegre, Flavia Longo, Enric Carcereny, Radj Gervais, Bartomeu Massuti, Ramon Palmero, Antonio Ramón Gómez-García, Rut Porta, Teresa Morán-López, Amelia Insa, Filippo de Marinis, Romain Corre, Isabel Bover, Noemi Reguart, Dolores Isla, Rosario Garcia-Campelo, Maria Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, Miguel Ángel Molina-Gutiérrez, Miquel Taron
2012-02-27

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Cheolwon Suh
2012-10-01

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Enriqueta Felip, ESMO Guidelines Working Group
2011-02

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

Rafael Rosell, Paul Van Schil, Erik Thunnissen, Denise R. Aberle, 楊ハン池, Charles A Powell, Takashi Takahashi, Tetsuya Mitsudomi, Valerie W Rusch, Yasushi Yatabe, Elisabeth Brambilla, Ignacio I Wistuba, James R Jett, 坪井正博, Giorgio Scagliotti, Adi F Gazdar, David G Beer, Fred R Hirsch, Christian G Brambilla, Nagahiro Saijo, 野口雅之
2011-03-01

Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial

Karla V Ballman, Valerie W Rusch, Gail E Darling, David R Jones, Paul A Decker, Richard A Malthaner, Richard I Inculet, Rodney J Landreneau, Joe Putnam
2011-10

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Ravi Salgia, 方英柱, A John Iafrate, Jeffrey A Engelman, Keith D Wilner, Eunice L Kwak, D Ross Camidge, Jeffrey W Clark, Benjamin J Solomon, Alice T Shaw, Robert C Doebele, Marileila Varella-Garcia, Gregory J Riely
2011-08-08

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

Denis Moro-Sibilot
2010-03-29

Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer

Rodrigo Arriagada, Jean-Pierre Pignon
2010-05-20

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

Federico Cappuzzo, Giuseppe Giaccone, Emilio Esteban
2010-10-28

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

Mari Mino-Kenudson, Leena Gandhi, Daniel B Costa, Robert G. Maki, Ravi Salgia, Pasi A Jänne, Mark J Ratain, Daniel Haber, Lecia V Sequist, 方英柱, A John Iafrate, Jeffrey A Engelman, Keith D Wilner, Eunice L Kwak, D Ross Camidge, Jeffrey W Clark, Benjamin J Solomon, Alice T Shaw, James G Christensen, Marileila Varella-Garcia
2010-02

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
2010-06-24

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
2009-07-24

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

Robert C. Miller, Valerie W Rusch, David R Gandara, Gail E Darling, Andrew Turrisi
2009-09-18

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Yi-Long Wu, Chandra Belani, Maciej Krzakowski
2009-08-19

Screening for epidermal growth factor receptor mutations in lung cancer

Carlos Camps, Mariano Provencio, Christian Rolfo
2009-08-19

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Tony Mok, Yi-Long Wu
2008-05-27

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

Rafael Rosell, Jean-Yves Douillard, Thierry Le Chevalier, Jean-Pierre Pignon
2008-11-10

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

Constantin T Yiannoutsos
2008-07-20

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
2007-04-01

European trends in preoperative and intraoperative nodal staging: ESTS guidelines

Ramon Rami-Porta
2007-03-01

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer

Nico van Zandwijk, Giuseppe Giaccone, Paul E. Van Schil
2007-04-02

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Michael Kelley, Cancer and Leukemia Group B, Everett E Vokes
2007-06-01

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

Marcello Tiseo, Rafael Rosell, Frank V Fossella, Andrea Ardizzoni
2006-12-14

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

記事 - wd:Q46454623

Welcome to Inventaire

友達やコミュニティの図書館

もっと調べる

you are offline